DE60310896D1 - PHARMAZEUTISCHE ZUBEREITUNGEN ENTHALTEND NANOPARTIKEL VON 2-(4-ETHOXY-PHENYL)-3-(4-METHANSULPHONYL-PHENYL)-PYRAZOLOi1,5-BöPYRIDAZIN - Google Patents

PHARMAZEUTISCHE ZUBEREITUNGEN ENTHALTEND NANOPARTIKEL VON 2-(4-ETHOXY-PHENYL)-3-(4-METHANSULPHONYL-PHENYL)-PYRAZOLOi1,5-BöPYRIDAZIN

Info

Publication number
DE60310896D1
DE60310896D1 DE60310896T DE60310896T DE60310896D1 DE 60310896 D1 DE60310896 D1 DE 60310896D1 DE 60310896 T DE60310896 T DE 60310896T DE 60310896 T DE60310896 T DE 60310896T DE 60310896 D1 DE60310896 D1 DE 60310896D1
Authority
DE
Germany
Prior art keywords
phenyl
pyrazoloi1
bopyridazine
methansulphonyl
particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60310896T
Other languages
English (en)
Other versions
DE60310896T2 (de
Inventor
Jonathan Appleby
Martin Rolfe Hill
Simon Joseph Holland
Stephanie Lynn Pearson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of DE60310896D1 publication Critical patent/DE60310896D1/de
Application granted granted Critical
Publication of DE60310896T2 publication Critical patent/DE60310896T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60310896T 2002-03-15 2003-03-13 PHARMAZEUTISCHE ZUBEREITUNGEN ENTHALTEND NANOPARTIKEL VON 2-(4-ETHOXY-PHENYL)-3-(4-METHANSULPHONYL-PHENYL)-PYRAZOLOi1,5-BöPYRIDAZIN Expired - Fee Related DE60310896T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0206200.8A GB0206200D0 (en) 2002-03-15 2002-03-15 Pharmaceutical compositions
GB0206200 2002-03-15
PCT/EP2003/002698 WO2003077920A1 (en) 2002-03-15 2003-03-13 Pharmaceutical compositions comprising 2-(4-ethoxy-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo’1,5-bipyridazine in nanoparticulate form

Publications (2)

Publication Number Publication Date
DE60310896D1 true DE60310896D1 (de) 2007-02-15
DE60310896T2 DE60310896T2 (de) 2007-05-10

Family

ID=9933079

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60310896T Expired - Fee Related DE60310896T2 (de) 2002-03-15 2003-03-13 PHARMAZEUTISCHE ZUBEREITUNGEN ENTHALTEND NANOPARTIKEL VON 2-(4-ETHOXY-PHENYL)-3-(4-METHANSULPHONYL-PHENYL)-PYRAZOLOi1,5-BöPYRIDAZIN

Country Status (21)

Country Link
US (1) US20050153967A1 (de)
EP (1) EP1485098B1 (de)
JP (1) JP2005520824A (de)
KR (1) KR20040091133A (de)
CN (1) CN1642549A (de)
AT (1) ATE350038T1 (de)
AU (1) AU2003208709A1 (de)
BR (1) BR0307427A (de)
CA (1) CA2478758A1 (de)
DE (1) DE60310896T2 (de)
EA (1) EA007201B1 (de)
EC (1) ECSP045295A (de)
ES (1) ES2277634T3 (de)
GB (2) GB0206200D0 (de)
IS (1) IS7378A (de)
MX (1) MXPA04009008A (de)
NO (1) NO20043889L (de)
NZ (1) NZ534179A (de)
PL (1) PL372932A1 (de)
WO (1) WO2003077920A1 (de)
ZA (1) ZA200406553B (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1546128B1 (de) 2002-08-19 2006-05-03 Glaxo Group Limited Pyrimidinderivate als selektive cox-2-inhibitoren
GB0221443D0 (en) 2002-09-16 2002-10-23 Glaxo Group Ltd Pyridine derivates

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
DE69833464T2 (de) * 1997-09-05 2006-08-24 Glaxo Group Ltd., Greenford Pharmazeutische Zusammensetzung, enthaltend 2,3-Diaryl-PyrazoloÄ1,5-bÜPyridazin Derivate
CO5261556A1 (es) * 1999-12-08 2003-03-31 Pharmacia Corp Composiciones inhibidoras de ciclooxigenasa-2 que tiene rapido acceso de efecto terapeutico
PL202623B1 (pl) * 2000-06-28 2009-07-31 Smithkline Beecham Plc Sposób wytwarzania drobno zmielonego preparatu substancji leczniczej, drobno zmielona substancja lecznicza wytworzona tym sposobem i zawierająca ją kompozycja farmaceutyczna

Also Published As

Publication number Publication date
ES2277634T3 (es) 2007-07-16
EP1485098B1 (de) 2007-01-03
CN1642549A (zh) 2005-07-20
EP1485098A1 (de) 2004-12-15
EA007201B1 (ru) 2006-08-25
AU2003208709A1 (en) 2003-09-29
GB2402335B (en) 2005-10-12
NO20043889L (no) 2004-09-16
ATE350038T1 (de) 2007-01-15
US20050153967A1 (en) 2005-07-14
IS7378A (is) 2004-07-29
NZ534179A (en) 2006-07-28
CA2478758A1 (en) 2003-09-25
GB2402335A (en) 2004-12-08
DE60310896T2 (de) 2007-05-10
ECSP045295A (es) 2004-10-26
GB0419971D0 (en) 2004-10-13
BR0307427A (pt) 2004-12-28
ZA200406553B (en) 2005-09-22
JP2005520824A (ja) 2005-07-14
WO2003077920A1 (en) 2003-09-25
EA200400864A1 (ru) 2005-02-24
KR20040091133A (ko) 2004-10-27
PL372932A1 (en) 2005-08-08
GB0206200D0 (en) 2002-05-01
MXPA04009008A (es) 2004-12-07

Similar Documents

Publication Publication Date Title
ES2545205T3 (es) Combinación de azelastina y ciclesonida
EA200401019A1 (ru) Дозированная лекарственная форма для перорального применения, содержащая ингибитор pde 4 в качестве действующего вещества и поливинилпирролидон в качестве вспомогательного вещества
EA200500853A1 (ru) 2,4,6-тризамещённые пиримидины, являющиеся ингибиторами фосфотидилинозитол(pi)-3-киназы, и их применение при лечении рака
ME00318B (me) Nova kompozicija i njena upotreba
CY1108874T1 (el) ΧΡΗΣΗ ΤΩΝ ΑΝΑΣΤΟΛΕΩΝ Ι κΒ- ΚΙΝΑΣΗΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΠΟΝΟΥ
CY1108532T1 (el) Ενωσεις και συνθεσεις για την παροχη δραστικων παραγοντων
DE69907977D1 (de) Pyrrolobenzodiazepine
DE60030741D1 (de) Chinazoline verbindungen als heilmittel
PA8539901A1 (es) Novedosa sal de succinato de o-desmetil-venlafaxina
DE69922676D1 (de) N-aralkylaminotetraline als neuropeptid-y-y5-rezeptorliganden
BR0210122A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo
CY1111698T1 (el) Συνδυασμος που περιλαμβανει εναν ανταγωνιστη υποδοχεα ατ1 και εναν ενισχυτη εκκρισης ινσουλινης ή εναν ευαισθητοποιητη ινσουλινης
GEP20074123B (en) Amino acids with affinity for the alpha−2−delta−protein
DE60322412D1 (de) Pharmazeutische feste Dispersionen von Modafinil-Verbindungen
ES2421948T3 (es) Compuestos y composiciones para suministrar agentes activos
ATE260650T1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
CL2004001050A1 (es) Compuesto derivado de 3'-[4-oxo-3-{[(ciclopropil o 2,2,2-trifluoroetil)amino]carbonil}-1,8-naftiridin-1(4h)-il]-3-sustituido-1-1'-bifenil-4-il; composicion farmaceutica; y uso en el tratamiento o prevencion de asma, bronquitis cronica, enfermedad pul
ATE303384T1 (de) 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren
BRPI0415053B8 (pt) inibidor de glicoproteína-p, método para preparar o mesmo e composição farmacêutica que compreende o mesmo
BR0314843A (pt) Novo composto
GEP20074058B (en) 4-(7-halo-2-quino(xa) linyloxy-phenoxy-propionic acid derivatives as antineoplastic agents
GEP20063754B (en) Quinoline Derivatives and Use Thereof as Antitumor Agents
AU2001246999A1 (en) New neurokinin antagonists for use as medicaments
DE60310896D1 (de) PHARMAZEUTISCHE ZUBEREITUNGEN ENTHALTEND NANOPARTIKEL VON 2-(4-ETHOXY-PHENYL)-3-(4-METHANSULPHONYL-PHENYL)-PYRAZOLOi1,5-BöPYRIDAZIN
AR043016A2 (es) Un compuesto antimigranico eletriptan y composicion farmaceutica que lo contiene

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee